Literature DB >> 9140167

Familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC): a review of clinical, genetic and therapeutic aspects.

C Soravia1, B Bapat, Z Cohen.   

Abstract

Familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC) are two syndromes of colorectal cancer predisposition, inherited in an autosomal dominant fashion. They account for about 1% and 5-7% of all colorectal cancer cases, respectively. FAP is caused by germline mutations of a tumour suppressor gene, the adenomatous polyposis coli (APC) gene, whereas HNPCC results from genetic alterations of the DNA mismatch repair genes. Clinical manifestations in FAP include colonic as well as extracolonic sites (duodenum, eye, dental, nervous or connective tissues). In FAP, prophylactic colectomy is required in all affected patients and regular endoscopic check-up of the upper gastrointestinal tract is necessary to detect malignant transformation of duodenal polyps; medical management of complex desmoid tumours is preferred rather than surgery. In HNPCC, there are extracolonic associated endometrial, gastric, small bowel or brain carcinomas. At present time, for HNPCC patients, only preventive measures such as regular colonoscopic or gynecologic examinations are recommended, since prophylactic colectomy or hysterectomy are not considered to be routine procedures.

Entities:  

Mesh:

Year:  1997        PMID: 9140167

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  6 in total

1.  Genotype-phenotype correlations in attenuated adenomatous polyposis coli.

Authors:  C Soravia; T Berk; L Madlensky; A Mitri; H Cheng; S Gallinger; Z Cohen; B Bapat
Journal:  Am J Hum Genet       Date:  1998-06       Impact factor: 11.025

2.  The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas.

Authors:  J M Cunningham; C Y Kim; E R Christensen; D J Tester; Y Parc; L J Burgart; K C Halling; S K McDonnell; D J Schaid; C Walsh Vockley; V Kubly; H Nelson; V V Michels; S N Thibodeau
Journal:  Am J Hum Genet       Date:  2001-08-24       Impact factor: 11.025

3.  Patient preferences and National Health Service costs: a cost-consequences analysis of cancer genetic services.

Authors:  Gethin L Griffith; Rhiannon Tudor Edwards; J Mark G Williams; Jonathon Gray; Val Morrison; Clare Wilkinson; Jim Turner; Barbara France; Paul Bennett
Journal:  Fam Cancer       Date:  2008-09-27       Impact factor: 2.375

4.  Familial adenomatous polyposis-associated thyroid cancer: a clinical, pathological, and molecular genetics study.

Authors:  C Soravia; S L Sugg; T Berk; A Mitri; H Cheng; S Gallinger; Z Cohen; S L Asa; B V Bapat
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

5.  A micro costing of NHS cancer genetic services.

Authors:  G L Griffith; R Tudor-Edwards; J Gray; R Butler; C Wilkinson; J Turner; B France; P Bennett
Journal:  Br J Cancer       Date:  2005-01-17       Impact factor: 7.640

Review 6.  Cancer genetics services: a systematic review of the economic evidence and issues.

Authors:  G L Griffith; R T Edwards; J Gray
Journal:  Br J Cancer       Date:  2004-05-04       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.